Getting Digital Assets from Public–Private Partnership Research Projects through “The Valley of Death,” and Making Them Sustainable

Projects in public–private partnerships, such as the Innovative Medicines Initiative (IMI), produce data services and platforms (digital assets) to help support the use of medical research data and IT tools. Maintaining these assets beyond the funding period of a project can be a challenge. The reason for that is the need to develop a business model that integrates the perspectives of all different stakeholders involved in the project, and these digital assets might not necessarily be addressing a problem for which there is an addressable market of paying customers. In this manuscript, we review four IMI projects and the digital assets they produced as a means of illustrating the challenges in making digital assets sustainable and the lessons learned. To progress digital assets beyond proof-of-concept into widely adopted tools, there is a need for continuation of multi-stakeholder support tailored to these assets. This would be best done by implementing a structure similar to the accelerators that are in place to help transform startup businesses into growing and thriving businesses. The aim of this article is to highlight the risk of digital asset loss and to provoke discussion on the concept of developing an “accelerator” for digital assets from public–private partnership research projects to increase the chance that digital assets will be sustained and continue to add value long after a project has ended.

[1]  Barry S. Coller,et al.  Traversing the Valley of Death: A Guide to Assessing Prospects for Translational Success , 2009, Science Translational Medicine.

[2]  Lee Harland,et al.  Lowering industry firewalls: pre-competitive informatics initiatives in drug discovery , 2009, Nature Reviews Drug Discovery.

[3]  Barbara Zdrazil,et al.  Scientific competency questions as the basis for semantically enriched open pharmacological space development. , 2013, Drug discovery today.

[4]  Y. R. Storch Rudall,et al.  Business Model Generation , 2012 .

[5]  D. Butler Translational research: Crossing the valley of death , 2008, Nature.

[6]  Song Li,et al.  Mastering Translational Medicine: Interdisciplinary Education for a New Generation , 2014, Science Translational Medicine.

[7]  J. Soriano,et al.  The ERS Research Agency: the beginning , 2016, European Respiratory Journal.

[8]  S. Lonial,et al.  Academic, Foundation, and Industry Collaboration in Finding New Therapies , 2017, The New England journal of medicine.

[9]  Benchmarking the scientific output of the Innovative Medicines Initiative , 2015, Nature Biotechnology.

[10]  Brijesh Singh,et al.  The Lean Startup:How Today's Entrepreneurs Use Continuous Innovation to Create Radically Successful Businesses , 2016 .

[11]  Yike Guo,et al.  tranSMART: An Open Source and Community-Driven Informatics and Data Sharing Platform for Clinical and Translational Research , 2013, AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science.

[12]  J Chard,et al.  Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development , 2015, CPT: pharmacometrics & systems pharmacology.

[13]  Barbara Zdrazil,et al.  The Application of the Open Pharmacological Concepts Triple Store (Open PHACTS) to Support Drug Discovery Research , 2014, PloS one.